MAZE - NASDAQ

Maze Therapeutics, Inc.

Maze Therapeutics, Inc.

MAZEยทNASDAQ

$25.06

+3.2%
HealthcareBiotechnology

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.39B
EPS-3.0500
P/E Ratio-8.22
Earnings Date08/11/2026
Maze Therapeutics, Inc.

Maze Therapeutics, Inc. Fair Value Envelope

MAZE ยท NASDAQ

Our analysis suggests that MAZE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $25.06, this represents a potential HIDDEN relative to our calculated worth for Maze Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $25.06

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$96.6M
+ Cash & Equivalents$189.2M
Firm Value$92.7M
- Debt$23.3M
Equity Value$69.3M
/ Shares Outstanding48,076,885B
DCF Value$1
OVERVALUED BY 94%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$56.0M
-$28.0M
-$14.0M
-$7.0M
-$3.5M
-$1.7M
-$874.5K
-$437.3K
-$218.6K
-$109.3K
Maintenance CapEx
-$79.4K
-$39.7K
-$19.9K
-$9.9K
-$5.0K
-$2.5K
-$1.2K
-$620
-$310
-$155
Owner Earnings
-$56.0M
-$28.0M
-$14.0M
-$7.0M
-$3.5M
-$1.8M
-$875.8K
-$437.9K
-$218.9K
-$109.5K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$51.9M
-$24.0M
-$11.1M
-$5.1M
-$2.4M
-$1.1M
-$511.0K
-$236.6K
-$109.5K
-$50.7K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your MAZE research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.